D-erythro-MAPP
Based on 1 publication(s) in Google Scholar
D-erythro-MAPP (D-e-MAPP) is a ceramidase inhibitor, with an IC50 of 1-5 μM in vitro.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.65%
- CAS. Nr.: 143492-38-0
- Formel: C23H39NO2
- Molecular Weight:361.56
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-14113
2-Acetyl-4-tetrahydroxybutyl imidazoleS1P Lyase Inhibitor -
HY-116535
D-threo-PPMP hydrochlorideGlcCer Synthase Inhibitor -
HY-124955
proTAMEAPC Inhibitor -
HY-D0952
Acridine Orange baseFluorescent Dye -
HY-148292
C16-Sphingosine-1-phosphateEDG/S1P Receptor Ligand -
HY-165064
C2 L-Erythro ceramide (d18:1/2:0)Sphingolipid -
HY-116703
L-erythro-DihydrosphingosineEster Product -
HY-156208
C2 Adamantanyl galactosylceramide (d18:1/2:0)GlcCer Inhibitor -
HY-158940
N-Glycine 3'-sulfo galactosylsphingosineLyso-sulfatide (bovine) ammonium Analog
Publications Citing Use of MedChemExpress (MCE) D-erythro-MAPP
More
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HL-60 | IC50 |
1 μM
Compound: D-e-MAPP
|
Inhibition of alkaline ceramidase 2 in human HL-60 cells using 3H]C16-ceramide as substrate after 1 hr by liquid scintillation counting analysis
Inhibition of alkaline ceramidase 2 in human HL-60 cells using 3H]C16-ceramide as substrate after 1 hr by liquid scintillation counting analysis
|
[PMID: 23312611] |
| HL-60 | IC50 |
1 μM
Compound: D-e-MAPP
|
Inhibition of aCDase expressed in human HL60 cell extract
Inhibition of aCDase expressed in human HL60 cell extract
|
[PMID: 22989912] |
| MCF7 | IC50 |
30 μM
Compound: D-e-MAPP
|
Antiproliferative activity against human MCF7 cells after 48 hrs
Antiproliferative activity against human MCF7 cells after 48 hrs
|
[PMID: 17869115] |
In Vitro
D-erythro-MAPP (D-e-MAPP) reduces the viability of MCF-7 cells in a dose-dependent manner with IC50 value of 4.4 μM, and 15.6 μM, respectively[1].
D-erythro-MAPP (D-e-MAPP) induces G0/G1 arrest in cell cycle progression resulting in growth suppression[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
-
Cell Line:Human breast cancer MCF-7 cells.
-
Concentration:24 h.
-
Incubation Time:3.13-100 μM.
-
Result:Inhibited cell viability.
Chemical Information
-
CAS. Nr. 143492-38-0
-
Appearance Solid
-
Molecular Weight 361.56
-
Formel C23H39NO2
-
Color White to off-white
-
SMILES
O[C@@H](C1=CC=CC=C1)[C@@H](C)NC(CCCCCCCCCCCCC)=O
-
Synonyms
D-e-MAPP
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Adv Res
Targeting YTHDF2 inhibits tumorigenesis of diffuse large B-cell lymphoma through ACER2-mediated ceramide catabolism. [Abstract]2024 Sep:63:17-33. PMID: 37865189
Lösungsmittel & Löslichkeit
In Vitro:
DMF : ≥ 20 mg/mL (55.32 mM)
Ethanol : ≥ 20 mg/mL (55.32 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Hüseyin İzgördü, et al. Characteristics of apoptosis induction in human breast cancer cells treated with a ceramidase inhibitor. Cytotechnology. 2020 Dec;72(6):907-919. [Content Brief]
[2]. A Bielawska, et al. (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J Biol Chem. 1996 May 24;271(21):12646-54. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMF / Ethanol | 1 mM | 2.7658 mL | 13.8290 mL | 27.6579 mL | 69.1448 mL |
| 5 mM | 0.5532 mL | 2.7658 mL | 5.5316 mL | 13.8290 mL | |
| 10 mM | 0.2766 mL | 1.3829 mL | 2.7658 mL | 6.9145 mL | |
| 15 mM | 0.1844 mL | 0.9219 mL | 1.8439 mL | 4.6097 mL | |
| 20 mM | 0.1383 mL | 0.6914 mL | 1.3829 mL | 3.4572 mL | |
| 25 mM | 0.1106 mL | 0.5532 mL | 1.1063 mL | 2.7658 mL | |
| 30 mM | 0.0922 mL | 0.4610 mL | 0.9219 mL | 2.3048 mL | |
| 40 mM | 0.0691 mL | 0.3457 mL | 0.6914 mL | 1.7286 mL | |
| 50 mM | 0.0553 mL | 0.2766 mL | 0.5532 mL | 1.3829 mL |
D-erythro-MAPP Related Classifications
HY-137422 Related Classifications
Powered by Bioz